Meningoencephalitis

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Retrieved on: 
Tuesday, October 24, 2023
AD, Alzheimer's disease, Repeatable Battery for the Assessment of Neuropsychological Status, Vaccine, Meningoencephalitis, Prevalence, Dementia, Research, HIV disease progression rates, Test management, Alzheimer's Association, Cerebral amyloid angiopathy, Mini–Mental State Examination, Disease, Ace, MMSE, Swelling, Assessment, TMT, Emerging technologies, Patient, CAA, Pharmaceutical industry, Medical imaging

Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.

Key Points: 
  • Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.
  • Data confirm preliminary findings indicating a comparable safety profile between ABvac40 and placebo groups, with similar rates of treatment-emergent adverse events.
  • In addition, volumetric magnetic resonance imaging showed a lesser increase in whole brain atrophy in the ABvac40 group vs placebo.
  • The results reported for ABvac40 to date validate its clinical potential, positioning it as promising therapeutic candidate for early AD treatment.

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Retrieved on: 
Monday, July 17, 2023
Volunteering, PMN, Plaque, Therapy, PROMIS, AAN, Pharmacokinetics, American Academy, Multiple system atrophy, Solanezumab, QS-21, Antibody, Incidence, Meningoencephalitis, AAIC, ARIA, Patient, Immunoglobulin G, MSA, Risk, Poster, Neuroscience, Epitope, TSX, Abo, Surface plasmon resonance, FDA, American Academy of Neurology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ALS, IND, Food, Safety, Conference, Vaccine, Pharmaceutical industry, Paint, Publication

Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.

Key Points: 
  • Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.
  • The data were presented in posters on July 16, 2023, at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands.
  • “The increasingly recognized benefit of targeting oligomers of Aβ underscores the potential advantage of our PMN310 antibody and AβO vaccine candidates.
  • ProMIS presented a poster on its vaccine candidate being evaluated preclinically for the prevention of AD at AAIC.

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease

Retrieved on: 
Tuesday, April 25, 2023
Amyloid-related imaging abnormalities, PMN, Plaque, Therapy, PROMIS, Vaccination, AAN, American Academy, Multiple system atrophy, QS-21, Brain, Biomarker, Meningoencephalitis, ARIA, Patient, MSA, Risk, KLH, Annual general meeting, Neuroscience, Epitope, TSX, AD, American Academy of Neurology, Immunization, ALS, Disease, Vaccine

An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD.

Key Points: 
  • An AD vaccine capable of inducing an effective antibody response against pathogenic Aβ could potentially be administered as a preemptive measure to at-risk individuals to prevent the symptomatic disease or given therapeutically to diagnosed patients to inhibit the progression of AD.
  • Using computational modeling, ProMIS has identified conformational epitopes that are exposed on misfolded, toxic Aβ oligomers (AβO), the driver of disease, and not on monomers or plaque.
  • There were no potentially deleterious T helper cell responses to the conformational AβO peptide epitope, and T helper responses developed only against the KLH carrier protein.
  • These findings support potential clinical development of a therapeutic vaccine for AD that could elicit an antibody response while reducing the risk of meningoencephalitis, as well as ARIA.

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Monday, October 31, 2022
Mental Health, FDA, Health, Clinical Trials, General Health, Pharmaceutical, Safety, Immunization, Injection, Proline, Amyloid, Drug Quality and Security Act, Food, Inflammation, Brain, Securities Act of 1933, Investigational New Drug, Nature, Charles River Laboratories, U.S. Securities and Exchange Commission, Leukapheresis, Patient, Forward-looking statement, DC, Dementia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, IIA, Membrane, Immunotherapy, Securities Exchange Act of 1934, University, FDA, Bipolar disorder, IND, Post-traumatic stress disorder, Major depressive disorder, Risk, MDD, PTSD, Meningoencephalitis, Monocyte, Nasdaq, Lithium, Pharmaceutical industry, Vaccine

We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.

Key Points: 
  • We are grateful to receive this timely, favorable response from the FDA to initiate a Phase I/IIA trial with ALZN002.
  • We are advancing the process and expect that the first patient will be dosed in the first quarter of 2023.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The IND supports initial deployment of a Phase I/IIA clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group study.

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Retrieved on: 
Thursday, September 29, 2022
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, Safety, Bipolar disorder, Injection, Meningoencephalitis, Brain, FDA, Food, Drug Quality and Security Act, MDD, U.S. Securities and Exchange Commission, IND, Antibody, Nature, Proline, Securities Act of 1933, DC, Immunization, Immunotherapy, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Patient, Risk, Major depressive disorder, Nasdaq, Dementia, Post-traumatic stress disorder, Amyloid, Monocyte, University, Immune system, Leukapheresis, PTSD, Lithium, Human, Charles River Laboratories, Vaccine, Pharmaceutical industry

The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.

Key Points: 
  • The product candidate is designed to treat mild to moderate dementia of the Alzheimers type.
  • ALZN002 is a proprietary active immunotherapy product, which means it is produced by each patients immune system.
  • The submitted IND supports initial deployment of a clinical trial, ALZN002-01, a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, Phase I/IIA clinical trial.
  • ALZN002 immunotherapy is intended to treat patients diagnosed with Alzheimers by inducing the patients own antibodies.

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

Retrieved on: 
Monday, May 9, 2022
Immunogenicity, University, National Institute on Aging, CSF, ADCS, Hospital, National, Massachusetts General Hospital, RU, NO, Ageing, DS, Hoffmann-La Roche, Antibody, JAMA Neurology, Tau, AD, Eli Lilly and Company, NASDAQ, Pyroglutamic acid, Company, Barrow Neurological Institute, Plasma, AC, Neurodegeneration, Neurology, Program, SG, Disease, Neurotoxicity, CH, University of California, San Diego, Compliance, MD, Medical director, GB, Down syndrome, National Institute, Janssen Pharmaceuticals, GLOBE, Death, Keck School of Medicine of USC, Medicine, Precision medicine, Genentech, AU, Investor, Conference, Meningoencephalitis, Pharmaceutical industry, Vaccine, Amyloid beta, EU, Degenerative disease, Safety

LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.

Key Points: 
  • Dr. Michael Rafii commented: The data published today in JAMA Neurology demonstrate that interventional clinical trials can be successfully conducted in individuals with Down syndrome.
  • Importantly, the ACI-24 anti-Abeta vaccine was safe, well-tolerated and an anti-Abeta immune response was observed in ACI-24-treated but not placebo-treated participants.
  • Rafii MS et al, Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome, A Phase 1b Randomized Clinical Trial, JAMA Neurology, 2022 May 9:79(5).
  • This randomized, double-blind, placebo-controlled, dose-escalation, phase 1b multi-center study reported in JAMA Neurology included 16 adults, aged 25-41 years.